Back كاسيريفيماب/إيميفيماب Arabic Kasirivimab/imdevimab Czech Casirivimab/Imdevimab German Κασιριβιμάμπη/ιμντεβιμάμπη Greek Casirivimab/imdevimab English Casirivimab/imdevimab Spanish REGN-COV2 French カシリビマブ・イムデビマブ Japanese REGN-COV2 Korean REGN-COV2 NB
 REGN10933 (blau) i REGN10987 (taronja) units a la proteïna S del SARS-CoV-2 (rosa). | |
| Malaltia objecte | COVID-19  |
|---|---|
| DrugBank | DB15691 |
Casirivimab/imdevimab és un medicament experimental desenvolupat per l'empresa nord-americana de biotecnologia Regeneron Pharmaceuticals. Es tracta de la barreja de dos anticossos monoclonals, casirivimab (REGN10933) i imdevimab (REGN10987),[1][2] combinació destinada a atacar al coronavirus SARS-CoV-2 responsable de la COVID-19.[3][4] Combinació destinada a evitar la fugida mutacional.[5]
- ↑ Morelle, Rebecca «Antibody treatment to be given to Covid patients». BBC News Online, 14-09-2020.
- ↑ «Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19», 03-09-2020.
- ↑ Kelland, Kate «Regeneron's antibody drug added to UK Recovery trial of COVID treatments». Reuters, 14-09-2020.
- ↑ «Regeneron's COVID-19 Response Efforts».
- ↑ «Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies». Science, 369, 6506, 8-2020, pàg. 1014–1018. DOI: 10.1126/science.abd0831. PMC: 7299283. PMID: 32540904.